Previous investigation reported that approximately 60% of EGFR-mutated NSCLC patients with acquired resistance to the first- or second-generation EGFR-TKIs would develop a new mutation within the drug target (Westover et al., 2018). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.